Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 22, Issue 1, 2016, Pages 275-283

  Haruyama, Yukihiro ^a   Kataoka, Hiroaki ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Companion diagnostics; Enzyme linked immunosorbent assay; Glypican 3; Hepatocellular carcinoma; Immunohistochemistry; Prognosis

Indexed keywords

CYTOTOXIC ANTIBODY; GLYPICAN 3; MOLECULAR MARKER; PEPTIDE VACCINE; GLYPICAN; GPC3 PROTEIN, HUMAN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; DRUG TARGETING; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PROTEIN FUNCTION; REVIEW; TISSUE SECTION; BLOOD; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; DISEASE COURSE; GENE EXPRESSION; GENETICS; IMMUNOTHERAPY; LIVER NEOPLASMS; PROGNOSIS;

BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; GENE EXPRESSION; GLYPICANS; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; PROGNOSIS;

EID: 84953432816     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i1.275     Document Type: Review

References (83)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]
3. Filmus J, Capurro M. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. FEBS J 2013; 280: 2471-2476 [PMID: 23305321 DOI: 10.1111/febs.12126]
4. Filmus J, Capurro M, Rast J. Glypicans. Genome Biol 2008; 9: 224 [PMID: 18505598 DOI: 10.1186/gb-2008-9-5-224]
5. Iglesias BV, Centeno G, Pascuccelli H, Ward F, Peters MG, Filmus J, Puricelli L, de Kier Joffé EB. Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. Histol Histopathol 2008; 23: 1333-1340 [PMID: 18785116]
6. Paine-Saunders S, Viviano BL, Zupicich J, Skarnes WC, Saunders S. glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development. Dev Biol 2000; 225: 179-187 [PMID: 10964473 DOI: 10.1006/dbio.2000.9831]
7. Capurro MI, Xu P, Shi W, Li F, Jia A, Filmus J. Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev Cell 2008; 14: 700-711 [PMID: 18477453 DOI: 10.1016/j.devcel.2008.03.006]
8. Pilia G, Hughes-Benzie RM, MacKenzie A, Baybayan P, Chen EY, Huber R, Neri G, Cao A, Forabosco A, Schlessinger D. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 1996; 12: 241-247 [PMID: 8589713 DOI: 10.1038/ng0396-241]
9. Pellegrini M, Pilia G, Pantano S, Lucchini F, Uda M, Fumi M, Cao A, Schlessinger D, Forabosco A. Gpc3 expression correlates with the phenotype of the Simpson-Golabi-Behmel syndrome. Dev Dyn 1998; 213: 431-439 [PMID: 9853964 DOI: 10.1002/(SICI)1097-017 7(199812)213::43.0.CO;2-7]
10. Cano-Gauci DF, Song HH, Yang H, McKerlie C, Choo B, Shi W, Pullano R, Piscione TD, Grisaru S, Soon S, Sedlackova L, Tanswell AK, Mak TW, Yeger H, Lockwood GA, Rosenblum ND, Filmus J. Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome. J Cell Biol 1999; 146: 255-264 [PMID: 10402475 DOI: 10.1083/jcb.146.1.255]
11. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125: 89-97 [PMID: 12851874 DOI: 10.1016/S0016-5085(03)00689-9]
12. Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, Niki T, Shibahara J, Mori M, Makuuchi M, Hippo Y, Kodama T, Iwanari H, Aburatani H, Fukayama M. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005; 18: 1591-1598 [PMID: 15920546 DOI: 10.1038/modpathol.3800436]
13. Filmus J, Church JG, Buick RN. Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine. Mol Cell Biol 1988; 8: 4243-4249 [PMID: 3185547 DOI: 10.1128/MCB.8.10.4243]
14. Li M, Choo B, Wong ZM, Filmus J, Buick RN. Expression of OCI-5/glypican 3 during intestinal morphogenesis: regulation by cell shape in intestinal epithelial cells. Exp Cell Res 1997; 235: 3-12 [PMID: 9281346 DOI: 10.1006/excr.1997.3629]
15. Huber R, Mazzarella R, Chen CN, Chen E, Ireland M, Lindsay S, Pilia G, Crisponi L. Glypican 3 and glypican 4 are juxtaposed in Xq26.1. Gene 1998; 225: 9-16 [PMID: 9931407]
16. De Cat B, Muyldermans SY, Coomans C, Degeest G, Vanderschueren B, Creemers J, Biemar F, Peers B, David G. Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements. J Cell Biol 2003; 163: 625-635 [PMID: 14610063 DOI: 10.1083/jcb.200302152]
17. Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S, Tokita S, Iwanari H, Ito Y, Nakano K, Nezu J, Tsunoda H, Yoshino T, Ohizumi I, Tsuchiya M, Ohnishi S, Makuuchi M, Hamakubo T, Kodama T, Aburatani H. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for earlystage hepatocellular carcinoma. Cancer Res 2004; 64: 2418-2423 [PMID: 15059894 DOI: 10.1158/0008-5472.CAN-03-2191]
18. Capurro M, Filmus J. Glypican-3 as a serum marker for hepatocellular carcinoma. Cancer Res 2005; 65: 372; author reply 372-373 [PMID: 15665316]
19. Traister A, Shi W, Filmus J. Mammalian Notum induces the release of glypicans and other GPI-Anchored proteins from the cell surface. Biochem J 2008; 410: 503-511 [PMID: 17967162 DOI: 10.1042/BJ20070511]
20. Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res 1997; 57: 5179-5184 [PMID: 9371521]
21. Wang HL, Anatelli F, Zhai QJ, Adley B, Chuang ST, Yang XJ. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch Pathol Lab Med 2008; 132: 1723-1728 [PMID: 18976006 DOI: 10.1043/1543-2165-132.11.1723]
22. Zynger DL, Dimov ND, Luan C, Teh BT, Yang XJ. Glypican 3: a novel marker in testicular germ cell tumors. Am J Surg Pathol 2006; 30: 1570-1575 [PMID: 17122513 DOI: 10.1097/01. pas.0000213322.89670.48]
23. Saikali Z, Sinnett D. Expression of glypican 3 (GPC3) in embryonal tumors. Int J Cancer 2000; 89: 418-422 [PMID: 11008203 DOI: 10.1002/1097-0215(20000920)89::53.0.CO;2-I]
24. Kai K, Nakamura J, Ide T, Masuda M, Kitahara K, Miyoshi A, Noshiro H, Tokunaga O. Hepatoid carcinoma of the pancreas penetrating into the gastric cavity: a case report and literature review. Pathol Int 2012; 62: 485-490 [PMID: 22726068 DOI: 10.1111/j.1440-1827.2012.02814.x]
25. Hishinuma M, Ohashi KI, Yamauchi N, Kashima T, Uozaki H, Ota S, Kodama T, Aburatani H, Fukayama M. Hepatocellular oncofetal protein, glypican 3 is a sensitive marker for alpha-fetoproteinproducing gastric carcinoma. Histopathology 2006; 49: 479-486 [PMID: 17064293 DOI: 10.1111/j.1365-2559.2006.02522.x]
26. Kinjo T, Taniguchi H, Kushima R, Sekine S, Oda I, Saka M, Gotoda T, Kinjo F, Fujita J, Shimoda T. Histologic and immunohistochemical analyses of ?-fetoprotein-producing cancer of the stomach. Am J Surg Pathol 2012; 36: 56-65 [PMID: 22173117 DOI: 10.1097/PAS.0b013e31823aafec]
27. Takahashi N, Aoyama F, Hiyoshi M, Kataoka H, Sawaguchi A. Establishment and biological characterization of a novel cell line derived from hepatoid adenocarcinoma originated at the ampulla of Vater. Int J Oncol 2014; 44: 1139-1145 [PMID: 24481592 DOI: 10.3892/ijo.2014.2282]
28. Ushiku T, Uozaki H, Shinozaki A, Ota S, Matsuzaka K, Nomura S, Kaminishi M, Aburatani H, Kodama T, Fukayama M. Glypican 3-expressing gastric carcinoma: distinct subgroup unifying hepatoid, clear-cell, and alpha-fetoprotein-producing gastric carcinomas. Cancer Sci 2009; 100: 626-632 [PMID: 19243386 DOI: 10.1111/j.1349-7006.2009.01108.x]
29. Wang SK, Zynger DL, Hes O, Yang XJ. Discovery and diagnostic value of a novel oncofetal protein: glypican 3. Adv Anat Pathol 2014; 21: 450-460 [PMID: 25299314 DOI: 10.1097/PAP.0000000000000043]
30. Morford LA, Davis C, Jin L, Dobierzewska A, Peterson ML, Spear BT. The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and homeoboxes 2 and in the regenerating liver by alpha-fetoprotein regulator 2. Hepatology 2007; 46: 1541-1547 [PMID: 17668883 DOI: 10.1002/hep.21825]
31. Yamanaka K, Ito Y, Okuyama N, Noda K, Matsumoto H, Yoshida H, Miyauchi A, Capurro M, Filmus J, Miyoshi E. Immunohistochemical study of glypican 3 in thyroid cancer. Oncology 2007; 73: 389-394 [PMID: 18511877 DOI: 10.1159/000136159]
32. Maeda D, Ota S, Takazawa Y, Aburatani H, Nakagawa S, Yano T, Taketani Y, Kodama T, Fukayama M. Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol 2009; 22: 824-832 [PMID: 19329941 DOI: 10.1038/modpathol.2009.40]
33. Nakano K, Orita T, Nezu J, Yoshino T, Ohizumi I, Sugimoto M, Furugaki K, Kinoshita Y, Ishiguro T, Hamakubo T, Kodama T, Aburatani H, Yamada-Okabe H, Tsuchiya M. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun 2009; 378: 279-284 [PMID: 19022220 DOI: 10.1016/j.bbrc.2008.11.033]
34. Ishiguro T, Sugimoto M, Kinoshita Y, Miyazaki Y, Nakano K, Tsunoda H, Sugo I, Ohizumi I, Aburatani H, Hamakubo T, Kodama T, Tsuchiya M, Yamada-Okabe H. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res 2008; 68: 9832-9838 [PMID: 19047163 DOI: 10.1158/0008-5472. CAN-08-1973]
35. Takai H, Kato A, Ishiguro T, Kinoshita Y, Karasawa Y, Otani Y, Sugimoto M, Suzuki M, Kataoka H. Optimization of tissue processing for immunohistochemistry for the detection of human glypican-3. Acta Histochem 2010; 112: 240-250 [PMID: 19246079 DOI: 10.1016/j.acthis.2008.11.025]
36. Yorita K, Takahashi N, Takai H, Kato A, Suzuki M, Ishiguro T, Ohtomo T, Nagaike K, Kondo K, Chijiiwa K, Kataoka H. Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma. Liver Int 2011; 31: 120-131 [PMID: 20964802 DOI: 10.1111/j.1478-3231.2010.02359.x]
37. Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T, Nakatsura T. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 2009; 100: 1403-1407 [PMID: 19496787 DOI: 10.1111/j.1349-7006.2009.01206.x]
38. Ning S, Bin C, Na H, Peng S, Yi D, Xiang-hua Y, Fang-yin Z, Dayong Z, Rong-cheng L. Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients. Mol Biol Rep 2012; 39: 351-357 [PMID: 21655958 DOI: 10.1007/s11033-011-0745-y]
39. Yu MC, Lee YS, Lin SE, Wu HY, Chen TC, Lee WC, Chen MF, Tsai CN. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin. Ann Surg Oncol 2012; 19 Suppl 3: S455-S463 [PMID: 21822558 DOI: 10.1245/s10434-011-1946-2]
40. Wang YL, Zhu ZJ, Teng DH, Yao Z, Gao W, Shen ZY. Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation. World J Gastroenterol 2012; 18: 2408-2414 [PMID: 22654434 DOI: 10.3748/wjg.v18.i19.2408]
41. Fu SJ, Qi CY, Xiao WK, Li SQ, Peng BG, Liang LJ. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection. Surgery 2013; 154: 536-544 [PMID: 23601901 DOI: 10.1016/j.surg.2013.02.014]
42. Li J, Gao JZ, Du JL, Wei LX. Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-Analysis. World J Gastroenterol 2014; 20: 6336-6344 [PMID: 24876756 DOI: 10.3748/wjg.v20.i20.6336]
43. Xiao WK, Qi CY, Chen D, Li SQ, Fu SJ, Peng BG, Liang LJ. Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-Analysis. BMC Cancer 2014; 14: 104 [PMID: 24548704 DOI: 10.1186/1471-2407-14-104]
44. Anatelli F, Chuang ST, Yang XJ, Wang HL. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am J Clin Pathol 2008; 130: 219-223 [PMID: 18628090 DOI: 10.1309/WMB5PX57Y4P8QCT]
45. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, Ashihara H, Katagiri T, Furukawa Y, Fujiyama S, Ogawa M, Nakamura Y, Nishimura Y. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003; 306: 16-25 [PMID: 12788060 DOI: 10.1016/S0006-291X(03)00908-2]
46. Beale G, Chattopadhyay D, Gray J, Stewart S, Hudson M, Day C, Trerotoli P, Giannelli G, Manas D, Reeves H. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-Alcoholic and alcoholic fatty liver disease. BMC Cancer 2008; 8: 200 [PMID: 18638391 DOI: 10.1186/1471-2407-8-200]
47. Tangkijvanich P, Chanmee T, Komtong S, Mahachai V, Wisedopas N, Pothacharoen P, Kongtawelert P. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol 2010; 25: 129-137 [PMID: 19793164 DOI: 10.1111/j.1440-1746.2009.05988.x]
48. Liu H, Li P, Zhai Y, Qu CF, Zhang LJ, Tan YF, Li N, Ding HG. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol 2010; 16: 4410-4415 [PMID: 20845507 DOI: 10.3748/wjg.v16.i35.4410]
49. Yasuda E, Kumada T, Toyoda H, Kaneoka Y, Maeda A, Okuda S, Yoshimi N, Kozawa O. Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma. Hepatol Res 2010; 40: 477-485 [PMID: 20374302 DOI: 10.1111/j.1872-034X.2010.00624.x]
50. Ozkan H, Erdal H, Koçak E, Tutkak H, Karaeren Z, Yakut M, Köklü S. Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma. J Clin Lab Anal 2011; 25: 350-353 [PMID: 21919070 DOI: 10.1002/jcla.20484]
51. Qiao SS, Cui ZQ, Gong L, Han H, Chen PC, Guo LM, Yu X, Wei YH, Ha SA, Kim JW, Jin ZT, Li S, Peng JR, Leng XS. Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. Hepatogastroenterology 2003; 58: 1718-1724 [PMID: 21940340 DOI: 10.5754/hge11124]
52. Chen M, Li G, Yan J, Lu X, Cui J, Ni Z, Cheng W, Qian G, Zhang J, Tu H. Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma. Clin Chim Acta 2013; 423: 105-111 [PMID: 23643963 DOI: 10.1016/j.cca.2013.04.026]
53. Lee HJ, Yeon JE, Suh SJ, Lee SJ, Yoon EL, Kang K, Yoo YJ, Kim JH, Seo YS, Yim HJ, Byun KS. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut Liver 2014; 8: 177-185 [PMID: 24672660 DOI: 10.5009/gnl.2014.8.2.177]
54. Abd El Gawad IA, Mossallam GI, Radwan NH, Elzawahry HM, Elhifnawy NM. Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients. J Egypt Natl Canc Inst 2014; 26: 79-85 [PMID: 24841158 DOI: 10.1016/j.jnci.2014.01.001]
55. Yang SL, Fang X, Huang ZZ, Liu XJ, Xiong ZF, Liu P, Yao HY, Li CH. Can serum glypican-3 be a biomarker for effective diagnosis of hepatocellular carcinoma A meta-Analysis of the literature. Dis Markers 2014; 2014: 127831 [PMID: 25378766 DOI: 10.1155/2014/127831]
56. Haruyama Y, Yorita K, Yamaguchi T, Kitajima S, Amano J, Ohtomo T, Ohno A, Kondo K, Kataoka H. High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy. Int J Cancer 2015; 137: 1643-1651 [PMID: 25784484 DOI: 10.1002/ijc.29518]
57. Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005; 65: 6245-6254 [PMID: 16024626 DOI: 10.1158/0008-5472.CAN-04-4244]
58. Lai JP, Oseini AM, Moser CD, Yu C, Elsawa SF, Hu C, Nakamura I, Han T, Aderca I, Isomoto H, Garrity-Park MM, Shire AM, Li J, Sanderson SO, Adjei AA, Fernandez-Zapico ME, Roberts LR. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation. Hepatology 2010; 52: 1680-1689 [PMID: 20725905 DOI: 10.1002/hep.23848]
59. Zittermann SI, Capurro MI, Shi W, Filmus J. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer 2010; 126: 1291-1301 [PMID: 19816934 DOI: 10.1002/ijc.24941]
60. Gao W, Kim H, Ho M. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells. PLoS One 2015; 10: e0137664 [PMID: 26332121 DOI: 10.1371/journal. pone.0137664]
61. Wu Y, Liu H, Weng H, Zhang X, Li P, Fan CL, Li B, Dong PL, Li L, Dooley S, Ding HG. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway. Int J Oncol 2015; 46: 1275-1285 [PMID: 25572615 DOI: 10.3892/ijo.2015.2827]
62. Klymkowsky MW, Savagner P. Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol 2009; 174: 1588-1593 [PMID: 19342369 DOI: 10.2353/ajpath.2009.080545]
63. Li L, Jin R, Zhang X, Lv F, Liu L, Liu D, Liu K, Li N, Chen D. Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma. Hepatology 2012; 56: 1380-1390 [PMID: 22706665 DOI: 10.1002/hep.25891]
64. Viviano BL, Silverstein L, Pflederer C, Paine-Saunders S, Mills K, Saunders S. Altered hematopoiesis in glypican-3-deficient mice results in decreased osteoclast differentiation and a delay in endochondral ossification. Dev Biol 2005; 282: 152-162 [PMID: 15936336 DOI: 10.1016/j.ydbio.2005.03.003]
65. Mantovani A, Allavena P. The interaction of anticancer therapies with tumor-Associated macrophages. J Exp Med 2015; 212: 435-445 [PMID: 25753580 DOI: 10.1084/jem.20150295]
66. Takai H, Kato A, Kato C, Watanabe T, Matsubara K, Suzuki M, Kataoka H. The expression profile of glypican-3 and its relation to macrophage population in human hepatocellular carcinoma. Liver Int 2009; 29: 1056-1064 [PMID: 19141032 DOI: 10.1111/j.1478-3231.2008.01968.x]
67. Ohno A, Yorita K, Haruyama Y, Kondo K, Kato A, Ohtomo T, Kawaguchi M, Marutuska K, Chijiiwa K, Kataoka H. Aberrant expression of monocarboxylate transporter 4 in tumour cells predicts an unfavourable outcome in patients with hepatocellular carcinoma. Liver Int 2014; 34: 942-952 [PMID: 24433439 DOI: 10.1111/liv.12466]
68. Martinez-Outschoorn UE, Lisanti MP, Sotgia F. Catabolic cancerassociated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin Cancer Biol 2014; 25: 47-60 [PMID: 24486645 DOI: 10.1016/j.semcancer.2014.01.005]
69. Giannelli G, Rani B, Dituri F, Cao Y, Palasciano G. Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment. Gut 2014; 63: 1668-1676 [PMID: 25053718 DOI: 10.1136/gutjnl-2014-307323]
70. Greten TF, Wang XW, Korangy F. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut 2015; 64: 842-848 [PMID: 25666193 DOI: 10.1136/gutjnl-2014-307990]
71. Pan Q, Huang Y, Chen L, Gu J, Zhou X. SMAC-Armed vaccinia virus induces both apoptosis and necroptosis and synergizes the efficiency of vinblastine in HCC. Hum Cell 2014; 27: 162-171 [PMID: 24771354 DOI: 10.1007/s13577-014-0093-z]
72. Sidhu K, Kapoor NR, Pandey V, Kumar V. The "Macro" World of microRNAs in Hepatocellular Carcinoma. Front Oncol 2015; 5: 68 [PMID: 25859429 DOI: 10.3389/fonc.2015.00068]
73. Zhao C, Li Y, Zhang M, Yang Y, Chang L. miR-126 inhibits cell proliferation and induces cell apoptosis of hepatocellular carcinoma cells partially by targeting Sox2. Hum Cell 2015; 28: 91-99 [PMID: 25585946 DOI: 10.1007/s13577-014-0105-z]
74. Zhu AX, Gold PJ, El-Khoueiry AB, Abrams TA, Morikawa H, Ohishi N, Ohtomo T, Philip PA. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2013; 19: 920-928 [PMID: 23362325 DOI: 10.1158/1078-0432. CCR-12-2616]
75. Ikeda M, Ohkawa S, Okusaka T, Mitsunaga S, Kobayashi S, Morizane C, Suzuki I, Yamamoto S, Furuse J. Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma. Cancer Sci 2014; 105: 455-462 [PMID: 24521523 DOI: 10.1111/cas.12368]
76. Yen CJ, Daniele B, Kudo M, Merle P, Park JW, Ross P. Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma. J Clin Oncol 2014; 32 Suppl 5: 4102a
77. Nakatsura T, Komori H, Kubo T, Yoshitake Y, Senju S, Katagiri T, Furukawa Y, Ogawa M, Nakamura Y, Nishimura Y. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res 2004; 10: 8630-8640 [PMID: 15623647 DOI: 10.1158/1078-0432.CCR-04-1177]
78. Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, Matsui M, Torigoe T, Sato N, Baba H, Nishimura Y. Identification of HLA-A2-or HLAA24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006; 12: 2689-2697 [PMID: 16675560 DOI: 10.1158/1078-0432. CCR-05-2267]
79. Motomura Y, Ikuta Y, Kuronuma T, Komori H, Ito M, Tsuchihara M, Tsunoda Y, Shirakawa H, Baba H, Nishimura Y, Kinoshita T, Nakatsura T. HLA-A2 and-A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int J Oncol 2008; 32: 985-990 [PMID: 18425324]
80. Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, Nakagohri T, Takahashi S, Gotohda N, Takayama T, Yamao K, Uesaka K, Furuse J, Kinoshita T, Nakatsura T. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 2012; 18: 3686-3696 [PMID: 22577059]
81. Gao H, Li K, Tu H, Pan X, Jiang H, Shi B, Kong J, Wang H, Yang S, Gu J, Li Z. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res 2014; 20: 6418-6428 [PMID: 25320357 DOI: 10.1158/1078-0432. CCR-14-1170]
82. Gao W, Tang Z, Zhang YF, Feng M, Qian M, Dimitrov DS, Ho M. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis. Nat Commun 2015; 6: 6536 [PMID: 25758784 DOI: 10.1038/ncomms7536]
83. Feng M, Gao W, Wang R, Chen W, Man YG, Figg WD, Wang XW, Dimitrov DS, Ho M. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci USA 2013; 110: E1083-E1091 [PMID: 23471984 DOI: 10.1073/pnas.1217868110]